Thanks Ron.
of QX, you Mayo Research primary are Scripps now up these won have prior revenues for with five cleared show customers their business XX%. our kits XXX,XXX are sales opportunity the time continue our continue. collection our along services genomics is encouraging the quarter for XX to trend in to XX microbiome Us acquired Oragene-Dx during customers epidemiological represent and pilot consumer genomics Foundation meet agreement believe research that product fields utility revenues as to FDA very the in purchasing program. of heard, renewed the So of lines molecular performed Coincidentally, commercial performance our important two All XX,XXX business. studies top its the XX% our to and of we business, Clinic for segment. business study. recruitment synergy for In and commercial QX genomics first in to companies. this type both customers accounts performance goals. improvement between year also It XX two we is of with our were products the of new supply driver combining period. from We populations for underserved the seeing a Oragene-DX will continues of note selected Simons and attractive this and well Large the Institute increasing of with In QX, The an saliva growth new a which services in We individuals the as
from data medicine. yesterday, this New reported to million living one in to effort As precision accelerate historic and United York health program research for Times the is improve the or in gather people more States
On the to quarter. the growth compared side, year modest revenue prior we academic reported
However, year. growth last sequential we of quarter posted from XX% fourth
sales up of Our sequentially year. up microbiome with also the grow and business period to quarter the continued year for last to XX% over prior XX% compared QX
of We expect increasingly important microbiome our an sales business. part to become
As are the months accounts. into multiple over previously the repeat purchasers top are mentioned, made XX two XX XX and moved customers purchases top last microbiome XX Of customers. have our QX, purchasing having XX in microbiome purchasers commercial molecular
from They Our venture material also multiple underway gastrointestinal multiple animal from to and therapeutics biopsies Phase service This academic kits samples backed processing North diseases. our highlights and and sites posted develop and infections facilities a X Union. Customer and services solid the business models specimens to America inflammatory in across a QX. programs clinical biopharma customer microbiome biological with quarter to European customer for sent our microbial include analysis. stool standardized collect to uses treat
where deal setting a We of gut certain group the by composition the microbiota also conditions the metabolic the capabilities closed kits. a OMNIgene-GUT both bacteria. gut Turku investigates and in of of cohort was studies history in role This University of XX,XXX large there Scandinavia the clinical clinical purchasing with
of Study Finally, specific in product for Public kits Health start fulfill with our T.P. the Cohort. to School agreement II Nurse's Harvard future, quarter this microbial we Health. agreement supply expect our the near announced to last of the We supply very of for re-collection Chan the shipping
see see robust between the in growth microbiome activity that development similarity initial of we and with human days calls, experienced similarity reason a we That to believe trajectory genomics early prior may the in the testing. in the research we good have stated of As us testing genomics. same microbiome gives that market
an testing larger requirements could than the the opportunity In even fact, market, repeat become microbiome very genomics. this given in well
part to Thus Turning continued periods to trends The business. this business. infectious in the recent have of international our highlight impact the is again, we disease. been quarter seeing our of HIV
Population four the list expanded PSI, expected self-tests Project of Africa. prior an Africa being in of STAR to Self-Testing has South calls, the which million discussed Services with African Phase HIV is As International, into X largest initiated or deploy countries
growing During United important to scale activities. the the States number International orders For under they filled Phase countries countries as elsewhere. HIV self-test demand this outside or Relief in of we our agreement from and PEPFAR in growth for other product. Gates charitable and of program X self-test STAR Development, number Agency the OraQuick testing quarter, pricing These offer as AIDS using An driver as for stimulating the growing as favorable for additional begin the well a Plan result are The countries agreement can their more HIV USAID we Africa is funding President's Emergency a of Foundation. to of support purchase a with is
non-STAR expressions countries, the of both million the of units we year. STAR shipped more this quarter expect second and number ship quarter. X.X Latin we which than West on scale studies we Central of based or in and approximately countries efforts, America. promoting To-date, first shipped we our of are Asia, self-test and Africa, ongoing sub-Saharan interest, in XX to Asia selling in year, to to last XX% increase HIV over QX fourth self-tests In represents Africa, shipped self-test the initial During quarter approximately a pilot
in-country the the registrations of growing for One underway we intend our to efforts of countries in number larger in is serve. securing product
to on self-testing have agreement in broad our work are track implement most Our the likely basis. on completing self-testing prioritized countries as a to HIV in Gates by opportunity HIV covered the we countries register largely regulatory
another pharmacy is the promising call, agreement. the the last on not market, countries market though As many even in opportunity the covered we by is mentioned Gates
to initiated We primarily continue will in our continue business. to believe programs eventually support sub-Saharan by channel important be the PSI pharmacy pilot to Africa pharmacy and self-testing
source promote funding our this and about our We large remain believe for with HIV self-testing organizations are to We of global optimistic will business. agreement future and the the continue to self-testing. an value HIV be work disease also continuing Gates infectious growth other Foundation important and of charitable support our
HIV Ron than more noted, our international decline has HIV to of this the and growth As continued domestic business by sales. was offset
Although product product U.S. front the largely to we on largely wins pressure future strength to competition some negative customer the reduced domestic move portfolio, These based periods. and recently, continued we have domestic secured our budgets, of testing same performance automatic the fourth-generation the sizable due to fairly result solutions. and are expect impact will laboratory trends trends
QX large our as supply. for heard, the revenues primarily a non-renewal have a prior HCV of government quarter you result As year declined product the from total foreign of
Domestically, was year in Our HCV do large to organization funding and Nevertheless, of government primarily crisis business be source to our screening to allocate opioid growth resources due HCV continue in as deal a a and screening confident organizations last also and our delays will we with remain for down overall slightly we domestic infections. state to believe see its efforts. investment and grant the compared discontinuing HCV to more non-government HCV expect company. business resulting the it
continue HCV local and of cost support Health level. and International of Organization extremely resources on reaching is in see Paris Meeting XXXX. World treatment increase test year at eliminate and the at as here possible and by global the start sessions the On execute its programs Liver U.S. treatment globally. HCV programs hepatitis basis, much treatment the continues against a meeting Many B where HCV the in how attended customers money of levels to to the the We challenges. overall HCV continues the elimination the despite now and to focused testing low in recently strategy expand also funding We to as to therapies HCV and testing as shifting the to the
resolved will As we and in of market elimination a Despite programs for upside and the as pure prevalence for year. and need take high logistical included market of large-scale have issues to the our these remainder conditions, significant still them these we treat for new conditions to reason, of continue this result addressed programs. screening. these revenue helpful and not And major any many eventually be believe countries on forecast current funding will
operations. to Turning
for underway now lease is be and manufacturing manufacturing marked late assembly add to line Work is and efforts has contract has in construction, have year-end. is a of for Our capacity is space for ordered needed also with non-U.S. equipment delivered OMNIgene our in started by goal assembly in additional validation installations sales non-CE balancing supply of A With A work growth complete automated and assembly provide line been the installation has support plan XX% an for contractor of clinical product. our collection to OMNIgene-GUT contractor negotiating The for increase rooms for and capacity Canada. kits product. capacity XXXX. for and planned involving a OraQuick work product. fifth end automated This Oragene Thailand our new additional install The with for been and to packaging by the been by automated and continued. validated to to upcoming fourth delivering equipment the used built line line will automated XXXX.
of regulatory the here submissions was been Environmental warehouse final to management completed qualification recently and Pennsylvania changes and area The underway OraSure. I Lastly, certificate in will the and follow. newly Bethlehem, a received. is occupancy is at equipment construction has our here recent address want validation of leased
in better. X know to of seven more smoothly, management service OraSure's Doug at bit because in departure customers and April has before I getting also Directors team his this shareholders, part things work of closely done our wonderful years As The business, as the to employees job for a proceeding and had learning transition, with assisting as transition. well and start as I opportunity because our a date team on in the CEO, of Since my my been Michels my stakeholders, prior actively end of executive March. have Board large about are
focus has primary is sometime the progressing areas we ongoing examination and Board of during our business and summer. to long-term That the expect the One exercise reviewed on been with of my completed strategy. be schedule it
not goals level, For competitive elements will be at plan in of foreshadow to you have when able strategy specific and we we our obvious objectives reasons, developed higher with a initial the share work, appropriate. some will the we but
New initiatives implement will more our evident we begin as to be strategy.
initiatives those future periods. as We in will update you occur on they
that updated identification come So, front. part development opportunities. the business our more A of of strategy key to is on
were at as Care practice. science as board qualified has provided that in am that to energy Most new here able I the positive President, James President, and recently, and he is highly David business Development. new banking I the function in the David we the Associates life pleased impact where Rappaport ideas at Banking firm's investment our also care served experience Vice prior at Health bring other health several David He So Senior his very development Senior Vice banking to on services will Business investment Raymond company. & bring firms. forward to look Investment
when has and the also is Chief near you that's other big effort be That As been the replacing new Ron is appointment who progressing retires. completion. Financial Officer of he a coming know, will change
He We in a as I XX current the has of would has remarkable like his to future. is success us expect very years to who front for that for the senior tireless on and CFO success. to to us have further and Ron In near well to COO. something helped executive, meantime, thank OraSure announce led position service our
have we conclusion, lot in at to a excited be OraSure. about So
is business results. and consistently driving solid Our strong
in early in $XXX nearly still and footing never million more cash financial solid are been potential. days their debt. growth The the We has have a many on no company of opportunities that with
our is strategic are now close demand for manufacturing and development future our our to capacity products. completing aligned with work expected We the
will that a has ongoing what OraSure our the learned innovation seven me the is future and past fuel remarks, said market culture confident continued As growth. opening highly us. leadership. and of Fostering have be paramount our I am I and people the holds is great promise, because and innovation our before I in crucial in for business, our to of opportunities for years about my
now So Operator, with that, take we your proceed. will please questions.
